Studies on UBE2E3: Potential Drug Target and Biomarker (G10477)

Target Name: UBE2E3

NCBI ID: G10477

UBE2E3

Studies on UBE2E3: Potential Drug Target and Biomarker

UBE2E3 (UBE2E3 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the UBE2 family of transmembrane proteins, which are involved in a variety of cellular processes, including cell signaling and tissue structure.

UBE2E3 has been identified as a potential drug target due to its involvement in several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its function in these diseases has been studied extensively, and several studies have suggested that UBE2E3 may be a promising biomarker or drug target.

One of the main studies that has investigated UBE2E3 was a mouse model of Alzheimer's disease. In this study, researchers found that overexpression of UBE2E3 in mice led to an accumulation of neurofibrillary tangles and beta-amyloid plaques, which are hallmarks of Alzheimer's disease. This suggests that UBE2E3 may be a useful biomarker for diagnosing and understanding the underlying causes of Alzheimer's disease.

Another study that has investigated UBE2E3's role in cancer was a report published in the journal Oncogene. In this study, researchers found that UBE2E3 was expressed in various types of cancer, including breast, lung, and ovarian cancer. They also found that UBE2E3 was associated with cancer progression and the development of drug resistance. These findings suggest that UBE2E3 may be a useful drug target or biomarker for cancer treatment.

In addition to its potential role in disease, UBE2E3 has also been studied for its potential drug targets. Several studies have suggested that UBE2E3 may be a target for small molecules, including inhibitors of tyrosine kinase signaling pathways, which are involved in cell signaling. These studies also suggest that UBE2E3 may be a target for monoclonal antibodies, which are laboratory-produced molecules that can bind to specific proteins.

Overall, UBE2E3 is a protein that has been extensively studied for its potential role in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its function in these diseases has led to its identification as a potential drug target or biomarker. Further research is needed to fully understand the role of UBE2E3 in these diseases and to develop effective treatments.

Protein Name: Ubiquitin Conjugating Enzyme E2 E3

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-, as well as 'Lys-63'-linked polyubiquitination. Participates in the regulation of transepithelial sodium transport in renal cells. May be involved in cell growth arrest

The "UBE2E3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2E3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets